Navigation Links
ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R)
Date:10/23/2007

ZymoGenetics of TKIs and IL-21 found that IL-21 had additive anti-tumor effects when combined with a TKI in a renal cell cancer model.

Previous IL-21 studies

Previous clinical studies with IL-21 have shown that IL-21 is an active cytokine that can be administered in an outpatient regimen. Results from a Phase 1 study presented at the American Society of Clinical Oncology (ASCO) 2006 annual meeting showed that IL-21 administration was well tolerated in an outpatient setting, and that reductions in tumor size, including clinical responses per RECIST criteria, were observed in several patients. Available clinical data support further clinical investigation of IL-21 as a new therapeutic agent for the treatment of cancer.

About IL-21

IL-21 has potent biological activity in regulating key classes of immune cells, including cytotoxic T cells and natural killer cells. These cell types play important roles in eliminating malignant and infected cells. Based upon the ability of IL-21 to inhibit tumor growth in a number of animal models, ZymoGenetics is developing IL-21 for the treatment of cancer, initially in metastatic melanoma and renal cell carcinoma, and has retained commercialization rights for IL-21 in North America. The company licensed commercialization rights outside of North America to Novo Nordisk A/S.

About ZymoGenetics

ZymoGenetics creates novel protein drugs with the potential to significantly help patients fight their diseases. The company is developing a diverse pipeline of product candidates that are moving into and through clinical development. These candidates span a wide array of clinical opportunities that include bleeding, autoimmune and viral diseases and cancer. ZymoGenetics intends to commercialize these product candidates through internal development, collaborations with partners, and out-licensing of patents from its extensive patent portfolio. For further information, visit '/>"/>

SOURCE ZymoGenetics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 Larry J. Merlo , President ... will speak before the National Press Club in ... recent move to stop selling tobacco products and its leadership ... health. "Dramatic changes in our health care system ... government," Merlo has said. "CVS Health has a truly unique ...
(Date:9/19/2014)... , Sept. 19, 2014  Lpath, Inc. ... in bioactive lipid-targeted therapeutics, announced today that it ... registered shares of common stock and 3,605,042 unregistered ... purchase price for one registered share of common ... unregistered share of common stock will be $3.475.  ...
(Date:9/19/2014)... 19, 2014  Over 200 runners participated in the ... the Radiation Oncology Institute (ROI), hosted by Radiation Business ... Park in San Francisco.  "Donations are ... of Radiation Business Solutions, "but at this point, ... $70,000 for the ROI this year. This surpasses last ...
Breaking Medicine Technology:CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3
... today that it will partner with Direct Relief USA ... shots to community clinic and health center patients who ... organization that works with 1,100 clinics and health centers ... and supplies for their low-income and uninsured patients.  Most ...
... Colo., Sept. 8 N30 Pharmaceuticals, LLC today announced ... a first-in-class inhibitor of s-nitrosoglutathione reductase (GSNOR). ... administered to human beings. N6022 has the potential to ... human diseases, such as asthma, chronic obstructive pulmonary disease ...
Cached Medicine Technology:CVS Caremark to Offer $5 Million in Free Flu Shots to Uninsured Patients of Community Clinics and Health Centers Beginning September 20 2CVS Caremark to Offer $5 Million in Free Flu Shots to Uninsured Patients of Community Clinics and Health Centers Beginning September 20 3CVS Caremark to Offer $5 Million in Free Flu Shots to Uninsured Patients of Community Clinics and Health Centers Beginning September 20 4N30 Pharma Initiates Phase 1 Trials of Novel Reductase Inhibitor 2
(Date:9/19/2014)... 2014 Are you tired of having ... with seasonal allergies or sinus congestion? Fortunately, an inventor ... , She conceived of Nose Pal to avoid ... nose in public. Since it prevents nasal drip and ... conditions, particularly when cooking or working closely with others. ...
(Date:9/19/2014)... (HealthDay News) -- As kids transition from elementary to ... according to a recent study. But the ... found that verbal and physical bullying declines as students ... and prevention strategies must address all types of bullying ... girls, the researchers said. The study was published recently ...
(Date:9/19/2014)... Phoenix, AZ (PRWEB) September 19, 2014 Hastings ... over 30 years in the industry, announces a record number ... firm handles a wide variety of serious injury cases as ... cases along with dog bite related accident cases and others. ... Hastings and Hastings has stood the test of time when ...
(Date:9/19/2014)... According to a report from HarrisMartin ... Xarelto, named as defendants in several lawsuits filed in ... the court to dismiss those suits because the alleged ... with Philadelphia.* The cases include, for instance, Fontan v. ... Comm. Pls., Philadelphia Cty.), which was brought by a ...
(Date:9/19/2014)... 2014 (HealthDay News) -- Your brain structure could help predict ... study suggests. Researchers at Yale University found those with ... the parietal cortex may be more likely to engage in ... , , The study, funded by the U.S. National Institute ... women living in the Northeast. The researchers sought to determine ...
Breaking Medicine News(10 mins):Health News:Nasal Drip Eliminator Invented by InventHelp Client (LCC-218) 2Health News: Cyberbullying Seems to Ramp Up in Middle School 2Health News:Hastings And Hastings Announces a Record Number of Visitors to Its New Phoenix Personal Injury Website 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Brain Structure Might Help Predict Risky Behavior 2
... Wants Consumers to Go Back to the Basics: Healthy Living ... Chance to Win a Luxury Resort & Spa ExperienceWESTCHESTER, Ill., ... people who make New Year,s resolutions fall off the wagon ... we give ourselves such lofty expectations in the first place? ...
... NEW YORK, March 5 HMS Holdings Corp. ... for government healthcare programs, today announced the promotions ... Christina Dragonetti to Executive Vice President, Commercial Markets; ... Markets. These promotions follow the company,s announcement on ...
... AED industry-leading commitment to research and developmentGrand opening ... the American Academy of Dermatology (AAD)HAYWARD, Calif., March ... SLTM ) today announced the opening of the ... new product development, facilitate research on the innovative ...
... AAD Launches include New Technologies, Innovative Applications and New ... several new launches at the upcoming 67th annual meeting ... CA. Aligned with the company,s strategic imperative to stay ... launches will focus on the company reinforcing its ...
... they,re better able to play sports, be accepted by ... to glasses, contact lenses improve how children feel about ... acceptance among friends, a study of 484 nearsighted children ... spectacle wear on self-perception and the perception of others, ...
... Broadcasts of The Patient Channel and The Newborn ... Wegener Corporation (Nasdaq: WGNR ), a ... data distribution networks worldwide, today announced that the ... division of the iVillage Networks, recently upgraded its ...
Cached Medicine News:Health News:Samantha Harris Launches 'A Toast for Everyday Health' 2Health News:Samantha Harris Launches 'A Toast for Everyday Health' 3Health News:Samantha Harris Launches 'A Toast for Everyday Health' 4Health News:HMS Holdings Corp. Announces Executive Promotions 2Health News:Solta Medical, Inc. Announces State-of-the-Art Aesthetic Center 2Health News:Solta Medical, Inc. Announces State-of-the-Art Aesthetic Center 3Health News:Aesthera Announces Breakthrough Innovations at 2009 American Academy of Dermatology (AAD) Meeting 2Health News:Aesthera Announces Breakthrough Innovations at 2009 American Academy of Dermatology (AAD) Meeting 3Health News:Aesthera Announces Breakthrough Innovations at 2009 American Academy of Dermatology (AAD) Meeting 4Health News:Contact Lenses Boost Kids' Self-Image 2Health News:NBC Digital Health Network Upgrades WEGENER(R) Compel(R) Network Control System and Adds MediaPlan(R) Content Management System 2Health News:NBC Digital Health Network Upgrades WEGENER(R) Compel(R) Network Control System and Adds MediaPlan(R) Content Management System 3Health News:NBC Digital Health Network Upgrades WEGENER(R) Compel(R) Network Control System and Adds MediaPlan(R) Content Management System 4Health News:NBC Digital Health Network Upgrades WEGENER(R) Compel(R) Network Control System and Adds MediaPlan(R) Content Management System 5
Singe-pull lace design provides easy-on application to provide support and immobilization of the wrist while preserving finger mobility...
ManuTrain is an active wrist support that has optional features for increased stabilization....
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
... 3-Point® Polycentric Hinged Ulnar Deviation Splint uses ... the hand with ulnar deviation at the ... grasp or pinch. Radial and ulnar polycentric ... unimpeded flexion and extension. Padded, malleable finger ...
Medicine Products: